Sanofi buys US haemophilia drugmaker for $11.6 billion
Bloomberg Sanofi SA agreed to buy Bioverativ Inc., a spinoff from biotech giant Biogen Inc., for about $11.6 billion in a bid by France’s biggest drugmaker to gain treatments for rare blood disorders. The deal values haemophilia drugmaker Bioverativ at $105 a share, according to a statement from Sanofi. Sanofi shares fell 2.6 percent to 71.05 euros at 9:18 am ...
Read More »